{"entity":{"id":"2028","kind":"year","name":"2028 in oncology","aka":["2028"],"tldr":"Everything OnCo dates to 2028: 18 entries, 18 expected dates. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"18 dated entries in OnCo fall in 2028: 18 expected dates.\n\nOf those, 13 to the day and 5 to the month. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2027","2029"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2028,"events":[{"group":"expected","date":"2028-01","precision":"month","title":"LiGeR-HN1: primary completion","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"liger-hn1","refs":[]},{"group":"expected","date":"2028-02-29","precision":"day","title":"A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 10...","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct06376136","refs":[]},{"group":"expected","date":"2028-03-13","precision":"day","title":"IZABRIGHT-Breast01 primary completion: izalontamab brengitecan vs chemotherapy, first line, anti-PD-(L)1-ineligible (600 estimated participants)","note":"Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...","from":"tnbc-roadmap","refs":["izabright-breast01","izalontamab-brengitecan","bispecific-adc"]},{"group":"expected","date":"2028-04-04","precision":"day","title":"A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours: primary completion","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct06833008","refs":[]},{"group":"expected","date":"2028-04-30","precision":"day","title":"PATHFINDER 2 study completion (primary completion listed as 2026-02-11)","note":"Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.","from":"ctdna-tests","refs":["pathfinder-2","galleri"]},{"group":"expected","date":"2028-06","precision":"month","title":"RASolute 303 primary completion: daraxonrasib alone or with gemcitabine and nab-paclitaxel versus chemotherapy, first line metastatic (900 estimated participant...","note":"Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...","from":"pancreatic-roadmap","refs":["nct07491445","daraxonrasib","gemcitabine-nab-paclitaxel","idea-pdac-ras-inhibitor-combinations-and-sequencing"]},{"group":"expected","date":"2028-07-01","precision":"day","title":"OPT-IN (EA2197) primary completion: perioperative vs adjuvant chemotherapy for incidental gallbladder cancer (186 estimated participants)","note":"Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.","from":"gallbladder-cancer-roadmap","refs":["opt-in","incidental-gallbladder-cancer"]},{"group":"expected","date":"2028-07-01","precision":"day","title":"Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The P...","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct07509008","refs":[]},{"group":"expected","date":"2028-08-31","precision":"day","title":"A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast...","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct07784374","refs":[]},{"group":"expected","date":"2028-09","precision":"month","title":"CEB-01 in Locally Resectable Pancreatic Cancer: primary completion","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct06538857","refs":[]},{"group":"expected","date":"2028-09-15","precision":"day","title":"DAWN-303 primary completion: chemotherapy with or without INCB161734 in untreated KRAS G12D metastatic disease (588 estimated participants; recruiting)","note":"Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...","from":"pancreatic-roadmap","refs":["nct07522073","kras-inhibitors","idea-pdac-ras-inhibitor-combinations-and-sequencing"]},{"group":"expected","date":"2028-10","precision":"month","title":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.: primary completion","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct06590857","refs":[]},{"group":"expected","date":"2028-12","precision":"month","title":"A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC: primary completion","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct07798947","refs":[]},{"group":"expected","date":"2028-12-01","precision":"day","title":"HERIZON-BTC-302 primary completion: first-line zanidatamab with standard of care in HER2-positive biliary tract cancer (286 estimated participants)","note":"Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.","from":"gallbladder-cancer-roadmap","refs":["herizon-btc-302","zanidatamab","her2"]},{"group":"expected","date":"2028-12-07","precision":"day","title":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02): primary completion","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct06596694","refs":[]},{"group":"expected","date":"2028-12-30","precision":"day","title":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemoth...","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct07372079","refs":[]},{"group":"expected","date":"2028-12-31","precision":"day","title":"Alliance A021806 primary completion: perioperative versus adjuvant modified FOLFIRINOX for resectable pancreatic cancer (358 participants, actual; active, not r...","note":"Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...","from":"pancreatic-roadmap","refs":["folfirinox","neoadjuvant-adjuvant","idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease"]},{"group":"expected","date":"2028-12-31","precision":"day","title":"Capecitabine in Low Risk Triple Negative Breast Cancer: primary completion","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct06787339","refs":[]}]},"route":"/years/2028/","neighbours":{"year":[{"id":"2027","kind":"year","name":"2027 in oncology","route":"/years/2027/"},{"id":"2029","kind":"year","name":"2029 in oncology","route":"/years/2029/"}]}}